January 22nd, 2013
Trials of Niacin and AF Device Will Headline American College of Cardiology Program
Larry Husten, PHD
Two big trials will highlight this year’s American College of Cardiology (ACC) meeting in March in San Francisco. First is the PREVAIL trial testing Boston Scientific’s long-anticipated Watchman left atrial appendage closure device for stroke prevention in patients with atrial fibrillation (AF). Second is the detailed presentation of the controversial failed HPS2-THRIVE trial of extended-release niacin and laropiprant. The […]
January 22nd, 2013
Renal Denervation: Delineating Its Uses, Misuses, and Possibilities
Murray David Esler, MBBS PhD and John Ryan, MD
Is Renal Denervation a cure? A likely overused “magic bullet” in patients who should receive more behavior modification and drug treatment? Where exactly should it fit in our arsenal? John Ryan interviews Murray David Esler
January 21st, 2013
Selections from Richard Lehman’s Literature Review: January 21st
Richard Lehman, BM, BCh, MRCGP
This week’s topics include a review of drug-eluting stents and a summary of hypertrophic cardiomyopathy.
January 18th, 2013
Media Coverage of Research: Does It Sometimes Miss the Point?
Harlan M. Krumholz, MD, SM
Observing media coverage of a new study, Harlan Krumholz wonders if the spin misses the point of the research.
January 18th, 2013
A Possible Treatment for “Methods Myopia”
Leslie Curry, PhD, MPH
Yale researcher Leslie Curry offers a pithy primer on mixed-methods research — and on why it should matter to cardiologists who want to lead.
January 17th, 2013
Revisiting Novel Anticoagulants in Atrial Fibrillation
John Ryan, MD and Christian Thomas Ruff, MD, MPH
Two experts discuss the evolving landscape of novel anticoagulants for patients with AF. Do you agree with their perspectives? What questions do you have? What has your experience taught you?
January 16th, 2013
No Benefit of Darbepoetin Alfa in Heart Failure Patients with Anemia
Larry Husten, PHD
The bad news continues for Aranesp (darbepoetin alfa), Amgen’s long-acting erythropoietin-stimulating agent. The company today announced the top-line results of a large phase 3 heart-failure trial of the drug and said that the trial had failed to meet its primary endpoint. The RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial, which started in 2006, had randomized […]
January 16th, 2013
“Nostalgic Professionalism” or Actually Caring About Patients?
Ajay J Kirtane, MD, SM
Is caring about your patients when you’re not on duty becoming unacceptable?
January 14th, 2013
Selections from Richard Lehman’s Literature Review: January 14th
Richard Lehman, BM, BCh, MRCGP
This week’s topic is egg consumption and the risk of CHD and stroke.
January 14th, 2013
You’re Sick: To Work, or Not to Work?
Harlan M. Krumholz, MD, SM
When you’re sick do you feel torn between meeting your obligations and protecting patients from your illness?
NEJM Journal Watch — Recent Cardiology Articles- Oral Semaglutide Approved to Lower Cardiovascular Risk in High-Risk Patients with Type 2 Diabetes
- Covid-19 Vaccines Improve Heart Outcomes
- Detecting Atrial Fibrillation After Transient In-Hospital Episodes
- Cardiac Involvement with Mycoplasma pneumonia: More Common Than Previously Thought
- Amyloid in the Heart